Title
Accelerated longitudinal gait speed decline in HIV-infected older men

Permalink
https://escholarship.org/uc/item/1tt081q9

Journal
Journal of Acquired Immune Deficiency Syndromes, 70(4)

ISSN
1525-4135

Authors
Schrack, JA
Althoff, KN
Jacobson, LP
et al.

Publication Date
2015-12-01

DOI
10.1097/QAI.0000000000000731

Peer reviewed
Accelerated Longitudinal Gait Speed Decline in HIV-Infected Older Men

Jennifer A. Schrack, MS, PhD,* Keri N. Althoff, MPH, PhD,* Lisa P. Jacobson, PhD,* Kristine M. Erlandson, MD,† Beth D. Jamieson, PhD,‡ Susan L. Koletar, MD,§ John Phair, MD,∥ Luigi Ferrucci, MD, PhD,¶ Todd T. Brown, MD, PhD,# and Joseph B. Margolick, MD, PhD,* for the Multicenter AIDS Cohort Study

Background: Gait speed predicts functional decline, disability, and death and is considered a biomarker of biological aging. Changes in gait speed in persons aging with HIV may provide an important method of gauging health and longevity in an under assessed population. The objective of this study was to evaluate and quantify the rate of gait speed decline in HIV-infected (HIV+) men compared with HIV-uninfected (HIV−) men.

Methods: The study was nested in the Multicenter AIDS Cohort Study. The primary outcome was usual gait speed in meters per second measured between 2007 and 2013. Differences in the rate of gait speed decline and the incidence of clinically slow gait (<1.0 m/s) were assessed using multivariate linear regression models and Cox proportional hazards models, respectively.

Results: A total of 2025 men (973 HIV+ and 1052 HIV−) aged 40 years and older contributed 21,187 person-visits (9955 HIV+ and 11,232 HIV−) to the analysis. Average gait speeds at the age 50 years were 1.24 and 1.19 m/s in HIV+ and HIV− men, respectively (P < 0.001). In fully adjusted models, gait speed decline averaged 0.009 m/s per year after age 50 years (P < 0.001); this decline was 0.025 m/s per year greater in HIV+ men (P < 0.001). Moreover, HIV+ men had a 57% greater risk of developing clinically slow gait (adjusted hazard ratio = 1.57, 95% confidence interval: 1.27 to 1.91).

Conclusions: These findings indicate a faster rate of functional decline in HIV-infected men, suggesting greater risks of disability and death with advancing age.

Key Words: gait speed, HIV-infection, functional decline, disability, aging

(J Acquir Immune Defic Syndr 2015;70:370–376)
INTRODUCTION

Over 1.1 million people living in the United States are HIV infected (HIV+). Because of highly active antiretroviral therapy (HAART), those living with HIV now have the potential to live a long life; however, the long-term consequences of treated HIV infection on health and quality of life are unknown. It has been postulated that HIV infection may lead to an accelerated aging phenotype regardless of HIV virologic suppression, and due to a pro-inflammatory state and greater comorbidity burden present in those aging with HIV, and greater comorbidity burden present in those aging with HIV. As life expectancy of those living with HIV continues to increase, these factors may contribute to an accelerated rate of functional decline and disability.

Slow gait speed is a well-established predictor of functional decline, disability, and death in older adults. It has been associated with clinical progression of several chronic diseases in the general population, including diabetes, dementia, and congestive heart failure, and has been proposed as a method to distinguish between normal and pathological aging. Among HIV+ persons, slowed gait and an increased risk of poor functional performance have been observed compared with HIV− populations, yet larger sample sizes, a control group of similar HIV− adults, and longitudinal data are needed to better describe the trajectory of functional decline, and the risk of poor functional performance, by HIV status. Moreover, until recently, the HIV+ population has not been old enough to observe the onset and trajectory of the age-related decline in gait speed. Given the established prognostic power of gait speed, a systematic examination of the onset and rate of gait speed decline in a large population of HIV+ middle- and older-aged adults, relative to HIV− adults of similar demographics and lifestyle behaviors, may help define whether those living with HIV experience accelerated aging. Therefore, the purpose of this study was to test the hypothesis that HIV+ persons experience earlier and faster gait speed decline than HIV− persons. To this end, we analyzed gait speed measurements collected over a 6-year period in the Multicenter AIDS Cohort Study (MACS), an ongoing study of the history of HIV infection that includes HIV+ and HIV− men who have sex with men.

METHODS

Study Population

The MACS includes over 7000 HIV+ and demographically similar HIV− men who have sex with men enrolled in Baltimore/Washington, Chicago, Los Angeles, and Pittsburgh/Ohio in 1984–1985 (n = 4954), 1987–1991 (n = 668), 2001–2003 (n = 1350), and 2010–2013 (n = 17). Specific details of the study have been published. Briefly, participants complete semiannual study visits consisting of a standardized interview, physical examination, lifestyle questionnaires, and collection of blood for laboratory testing and storage. Informed consent is obtained from all study participants, and the institutional review boards at each study site approved the study protocol.

On October 1, 2007, the MACS began measuring gait speed at each study visit as part of a frailty assessment. This study includes 2025 MACS participants aged 40 years or older at baseline who contributed longitudinal gait speed assessments between October 1, 2007, and September 30, 2013. Baseline was defined as the first study visit at which a participant’s gait speed was measured.

Gait Speed

Gait speed was assessed over a 4-m course in the clinic corridor. Participants were asked to walk at their “normal comfortable pace.” Timing was initiated with a command of “Go” and stopped after the first foot fall over the finish line. Two measurements were conducted, with the faster used for analysis.

HIV Status

All men were assessed for HIV positivity by enzyme-linked immunosorbent assay and confirmed by Western blot. For HIV− men, HIV status was assessed at each study visit.

Covariates

Date of birth, race, and education were self-reported at enrollment. Cigarette smoking, drug use, and comorbidities were self-reported at each study visit during the analysis period. For analyses, smoking and drug use were dichotomized as “ever” or “never.” Race was dichotomized into white (non-Hispanic) or non-white. Education was defined as (1) less than high school, (2) high school or high school and some college, or (3) college degree or more. Hepatitis C infection was defined by detectable hepatitis C RNA in serum; and hepatitis B infection was defined by positive hepatitis B surface antigen. Mental health was assessed using the mental component summary (MCS) score of the SF-36 and was dichotomized as <42 or ≥42 for the analysis. Height and weight were measured using standard procedures, and body mass index was calculated as [mass (in kilograms)]/ [height (in meters)]². Hypertension was defined as systolic pressure >140 mm Hg, diastolic pressure >90 mm Hg, or self-reported diagnosis of hypertension with use of antihypertensive medications. Diabetes mellitus was defined as fasting glucose ≥126 mg/dL or self-reported previous diagnosis with use of diabetes medication. Liver disease was defined as current or past medical records confirmed diagnosis of liver disease not including infection with hepatitis B virus or hepatitis C virus. Arthritis was defined as prior or current self-reported arthritis pain. Peripheral neuropathy was defined as current or past report of pain, burning, numbness, or pins and needles sensation in the feet or legs or measured inability to detect a vibratory sensation in either foot.

T-lymphocyte subsets were measured at each MACS visit using standardized 3-color flow cytometry. Plasma HIV RNA concentrations (viral load) were measured using the Roche ultrasensitive assay (limit of detection = 50 copies/mL; Roche Diagnostics, Nutley, NJ). HAART was defined according to the US Department of Health and Human Services...
Kaiser Panel guidelines as 3 or more antiretroviral drugs including (1) a protease inhibitor, (2) a nonnucleoside reverse transcriptase inhibitor, (3) an entry or integrase inhibitor, or (4) 3 nucleoside reverse transcriptase inhibitors, including abacavir or tenofovir. AIDS was defined using the Centers for Disease Control and Prevention’s 1993 definition, excluding cases defined only by a CD4 T-cell count <200 cells per microliter and confirmed by review of medical records.

### Statistical Analysis

Two-sample t test and χ² test statistics were used to evaluate differences in continuous and categorical variables

### Table 1. Baseline Characteristics of Study Participants From October 1, 2007, to September 30, 2013 (N = 2025)

<table>
<thead>
<tr>
<th>HIV+ (n = 973)</th>
<th>HIV− (n = 1052)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>48.7 (6.9)</td>
<td>52.1 (8.3)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)*</td>
<td>25.5 (4.1)</td>
<td>27.3 (5.2)</td>
</tr>
<tr>
<td>Non-white†</td>
<td>387 (39.8%)</td>
<td>259 (24.6%)</td>
</tr>
<tr>
<td>College education‡</td>
<td>449 (46.1%)</td>
<td>643 (61.1%)</td>
</tr>
<tr>
<td>Smoking§</td>
<td>236 (24.3%)</td>
<td>288 (27.4%)</td>
</tr>
<tr>
<td>History of drug use∥</td>
<td>484 (49.8%)</td>
<td>457 (43.4%)</td>
</tr>
<tr>
<td>Alcohol use¶</td>
<td>3.1 (6.8%)</td>
<td>5.2 (9.6%)</td>
</tr>
<tr>
<td>Diabetes#</td>
<td>125 (12.8%)</td>
<td>103 (9.8%)</td>
</tr>
<tr>
<td>Liver disease**</td>
<td>37 (3.8%)</td>
<td>3 (&lt;1.0%)</td>
</tr>
<tr>
<td>Hypertension††</td>
<td>400 (41.6%)</td>
<td>429 (40.7%)</td>
</tr>
<tr>
<td>Arthritis‡‡</td>
<td>30 (3.1%)</td>
<td>38 (3.7%)</td>
</tr>
<tr>
<td>Peripheral neuropathy§§</td>
<td>329 (33.8%)</td>
<td>233 (22.2%)</td>
</tr>
<tr>
<td>SF-36 MCS∥∥∥</td>
<td>49.9 (11.6)</td>
<td>49.9 (12.1)</td>
</tr>
<tr>
<td>Hepatitis B infection¶¶¶</td>
<td>40 (4.1%)</td>
<td>7 (&lt;1.0%)</td>
</tr>
<tr>
<td>Hepatitis C infection####</td>
<td>151 (15.5%)</td>
<td>94 (8.9%)</td>
</tr>
<tr>
<td>Gait speed at age 50 (m/s)</td>
<td>1.19 (0.04)</td>
<td>1.24 (0.01)</td>
</tr>
<tr>
<td>Years since HAART¶¶¶</td>
<td>11.7 (8.2)</td>
<td>13.9 (8.2)</td>
</tr>
<tr>
<td>CD4 nadir (cells/µL)¶¶¶¶</td>
<td>309 (299.9)</td>
<td>309 (299.9)</td>
</tr>
<tr>
<td>Suppressed viral load§§§</td>
<td>629 (66.2%)</td>
<td>629 (66.2%)</td>
</tr>
</tbody>
</table>

Data are shown as mean and standard deviation (continuous variables) or number and percent (categorical variables).  
*Body mass index, calculated as weight in kilograms divided by height in meters squared.  
†Black (non-Hispanic), Black Hispanic, American Indian or Alaskan Native, Asian or Pacific Islander, other Hispanic, or other.  
‡Completed college degree or more.  
§Current or former smoker.  
∥History of any drug use.  
¶Number of drinks per week.  
#Fasting glucose ≥126 mg/dL or diagnosed with diabetes and use of medications.  
**Current or past confirmed diagnosis of liver disease.  
††Current or past confirmed diagnosis of hypertension and use of medications.  
‡‡Current or past report of arthritis pain.  
§§Current or past report of pain, burning, numbness, or pins and needles sensation in the feet or legs or measured inability to detect vibratory sensation in either foot.  
∥∥Short form 36 mental component summary score.  
¶¶Positive hepatitis B surface antigen.  
##Detectable hepatitis C RNA in serum.  
###Reported years from HIV diagnosis.  
####Reported years from HAART initiation.  
#####Lowest CD4 T-cell count, as measured or reported and confirmed with medical records.  
§§§<200 copies HIV RNA per milliliter.

Results

The study population consisted of the 2025 men (973 HIV+ and 1052 HIV−) aged 40 years and older who had 2 or more study visits between October 1, 2007, and September 30, 2013. These men contributed 21,187 person-visits (9955 HIV+ and 11,232 HIV−) to the analysis. The mean number of visits per participant was 10.2 (range: 2–17) for HIV+ men and 10.7 (range: 2–17) for HIV− men (P = 0.35). Baseline characteristics of these men are shown in Table 1. HIV+ participants were on average 3.4 years younger than HIV− participants and had lower body mass indexes (P < 0.001) and HIV+ participants were more likely to have liver disease, peripheral neuropathy, hepatitis B, and hepatitis C infection, be non-white, report a history of drug use, have fewer years of education, and were less likely to consume alcohol (P < 0.001). There was a wide range of gait speeds, from less than 0.14 m/s to more than 1.9 m/s, which is consistent with previous studies.12,26

Figure 1 displays the unadjusted mean and 95% confidence interval (CI) association between age and gait speed at age 50 years. The mean gait speeds were significantly lower for those with HIV+ compared to those with HIV−. A threshold for slow gait of less than 0.8 m/s was used as this threshold has been associated with increased risk for falls and mobility disability.4,5 Detection of diabetes and other metabolic characteristics was associated with increased risk of mobility disability, hospitalization, and death in the general aging population.6

Separate analyses of HIV+ men were performed to assess differences between those with and without slow gait by exposure to “di-drugs” (didanosine, stavudine, AZT (zidovudine), and efavirenz) and by time on HAART, using analyses of variance with Tukey–Kramer pairwise comparisons and pairwise logistic regression models. In additional analyses, use of these drugs was compared among 3 groups of HIV+ men: (1) those who never had slow gait, (2) those who had slow gait at baseline, and (3) those with incident slow gait during the study. All analyses were conducted using Stata SE version 13 (Statacorp, College Station, TX).
TABLE 2. Continuous Longitudinal Association Between Age and Gait Speed, Adjusted for HIV Serostatus and Other Confounding Variables, From October 1, 2007, to September 30, 2013 (N = 2025)

<table>
<thead>
<tr>
<th>Independent Variables</th>
<th>Coefficient</th>
<th>SE</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per year centered at 50 yrs)</td>
<td>−0.009</td>
<td>0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HIV infection</td>
<td>−0.025</td>
<td>0.007</td>
<td>0.001</td>
</tr>
<tr>
<td>HIV* age (per year centered at 50 yrs)</td>
<td>−0.002</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td>Weight (per kg)</td>
<td>−0.001</td>
<td>0.0002</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Height (per cm)</td>
<td>0.003</td>
<td>0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Non-white race</td>
<td>−0.084</td>
<td>0.009</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Education (yrs)</td>
<td>0.061</td>
<td>0.006</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>−0.012</td>
<td>0.004</td>
<td>0.005</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>−0.014</td>
<td>0.003</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Final longitudinal model assessing the associations among age, HIV, and gait speed decline. Smoking, history of drug and alcohol use, diabetes, liver disease, hypertension, arthritis, mental quality of life, and hepatitis B were not significant and were not included in the final model.

TABLE 3. Continuous Longitudinal Association Between Age and Gait Speed Stratified by HIV Status From October 1, 2007, September 30, 2013 (N = 2025)

<table>
<thead>
<tr>
<th>Dependent Variable: Gait Speed (m/s)</th>
<th>HIV+ (n = 973)</th>
<th>HIV− (n = 1052)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Coefficient</td>
<td>SE</td>
</tr>
<tr>
<td>Age (centered at 50 yrs)</td>
<td>−0.012</td>
<td>0.0005</td>
</tr>
<tr>
<td>Height (per cm)</td>
<td>0.002</td>
<td>0.0001</td>
</tr>
<tr>
<td>Weight (per kg)</td>
<td>−0.0007</td>
<td>0.0003</td>
</tr>
<tr>
<td>Non-white race</td>
<td>−0.073</td>
<td>0.011</td>
</tr>
<tr>
<td>Education</td>
<td>0.058</td>
<td>0.009</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>−0.010</td>
<td>0.006</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>−0.016</td>
<td>0.004</td>
</tr>
<tr>
<td>CD4 nadir (per increase of 50 cells/μL)</td>
<td>0.002</td>
<td>0.001</td>
</tr>
<tr>
<td>Suppressed viral load*</td>
<td>−0.007</td>
<td>0.005</td>
</tr>
</tbody>
</table>

*Viral load <200 HIV RNA copies per milliliter.

DISCUSSION

The capacity to walk independently is a central component of independent living and essential to maintaining race and peripheral neuropathy or education. Smoking, history of drug and alcohol use, diabetes, liver disease, hypertension, arthritis, MCS score, and hepatitis B infection were not significant and were not included in the final model.

In analyses stratified by HIV status, there were strong negative associations between gait speed and age in both the HIV+ (β = −0.012 m/s per year, P < 0.001) and HIV− (β = −0.011 m/s per year, P < 0.001) groups (Table 3). Height, weight, race, education, and peripheral neuropathy contributed significantly to both HIV+ and HIV− models, but hepatitis C infection was significant only in the HIV− model. In the HIV+ model, there was a significant association between nadir CD4 T-cell count and gait speed decline (β = 0.002 m/s per year for each 50 cell/μL increase, P = 0.029), but suppressed viral load (<200 copies/mL) did not have a significant effect.

To provide clinical perspective, we examined the effect of HIV status on the time to development of slow gait speed (<1.0 m/s). As shown in Figure 2, the trajectories of time to slow gait were significantly different between HIV+ and HIV− men (P < 0.001), with 50% of the HIV+ men exhibiting slow gait by the age 57 years compared with the age 66 years among the HIV− men. In Cox proportional hazard models using age as the time metric and adjusting for the variables that were significant in the continuous analysis (height, weight, race, education, peripheral neuropathy, and hepatitis C), the hazard of developing slow gait was 57% greater for HIV+ compared with HIV− men (adjusted hazard ratio: 1.57; 95% CI: 1.27 to 1.91).

To examine the potential effects of treatment on the risk of slow gait, HIV+ men were stratified into 3 groups: (1) those who never had slow gait, (2) those who had slow gait at baseline, and (3) those who had incident slow gait during the study. There were no meaningful or statistically significant differences among these groups by cumulative years on HAART or by cumulative years on d4T, d4T, AZT, or efavirenz.
quality of life. To our knowledge, this study is the first to evaluate age-related gait speed decline prospectively in a large HIV+ population and compare these observations with a demographically similar HIV− population. In the general aging population, it has been suggested that a change in gait speed of 0.05 m/s or more is clinically meaningful. In this study, gait speed at the age 50 years was on average 0.05 m/s slower among HIV+ men compared with HIV− men, suggesting that a clinically meaningful difference in speed by HIV status exists in middle age. Moreover, the significant interaction between HIV and age indicates that the rate of gait speed decline intensifies with age among those with HIV. Overall, these results strongly support the hypothesis that HIV+ individuals experience earlier and faster gait speed decline than their HIV− peers.

Multiple factors have been associated with gait speed decline including decreased aerobic capacity, changes in body composition, threats to biomechanics (eg, arthritis, balance difficulty), and compromised energy utilization, signifying that slowed gait speed is a reflection of underlying biological and physiological challenges that develop with age. A typical 65-year-old individual lives with 2 or more comorbid conditions. The addition of chronic HIV infection to this comorbidity burden adds another layer of complexity to an aging system, even among the virologically controlled.

Although a link between reduced functional performance and HIV infection has been hypothesized, the majority of previous research has focused on the syndrome of frailty or on composite measures of performance. Richert et al analyzed gait speed over 10 m, along with the 5 times sit-to-stand test and 6-minute walk distance, in 354 middle-aged HIV+ participants (median age at baseline 46 years) and compared it with published data from the general aging population. After a 2-year follow-up period, findings included greater deterioration in the 5 times sit-to-stand test and 6-minute walk distance but no difference in

*FIGURE 1. Quadratic fit plot of the unadjusted association (mean and 95% CI) between gait speed (in meters per second) and age (in years) by HIV status.*

*FIGURE 2. Kaplan–Meier estimates of the proportion of participants with gait speed >1.0 m/s by years of age (x axis), stratified by HIV status (log rank to compare survival distributions, *P* < 0.001).*
median 10-m gait speed. In a study of injection drug users, Greene et al.\(^7\) found that after 5 years of follow-up, HIV\(^+\) participants had reduced physical performance and greater risk of mortality than HIV\(^-\) participants, but the rate of decline was not quantified or compared. This study demonstrates a statistically significant difference in the trajectory of gait speed decline between men aging with HIV and demographically similar HIV\(^-\) men. Given the increased risk of frailty and comorbidity burden that has been noted in those aging with HIV\(^7,32,35\) this raises the concern that greater morbidity and disability among those aging with HIV may be forthcoming.

Gait speed declined significantly faster in non-white men than in white men, and this was true for both HIV\(^+\) and HIV\(^-\) participants. This difference could not be explained by HIV infection, education, or peripheral neuropathy. Race-related differences in functional and mobility decline in the general aging population have been reported. In the Health, Aging and Body Composition study, older blacks showed higher rates of mobility loss than whites, with greater risk of developing mobility limitations over follow-up even after accounting for poor mobility at baseline.\(^36\) The mechanism of these differences is not known but is generally believed to be related to lifelong differences in socioeconomic status.\(^36,37\)

It is unclear from the current results how long-term antiretroviral treatment may affect gait speed decline. This is an important question, as nearly all of the HIV\(^+\) men in this study were receiving HAART, and the majority were virologically suppressed, characteristics that are likely to be similar in most populations aging with HIV. In this study, analyses of HIV\(^+\) men with and without slow gait at baseline, or with incident slow gait, yielded no evidence that cumulative exposure to specific antiretroviral drugs (ddI, d4T, AZT, efavirenz) was associated with slower gait speed. These findings should be replicated in other more diverse populations with greater power to detect differences by treatment. Moreover, the association between lower nadir CD4 cell count and faster decline in gait speed is consistent with previous research linking HIV with frailty\(^10,32,33,38\) and underscores the importance of early initiation of therapy and maintaining virologic suppression and sufficient CD4 cell count, particularly with advancing age.

The development of age-related chronic diseases in people with chronic HIV infection may be driven by a state of chronic inflammation. Although not having data on inflammatory markers is a limitation, stored samples will provide opportunities for future research. The negative association between hepatitis C and gait speed among the HIV\(^-\) participants may in part be explained by increased inflammatory burden and also warrants future investigation.

This study also was limited in its ability to assess the effect of HIV status on gait speed decline in those older than 65 years. As of September 2013, 24% of HIV\(^-\) MACS participants were 65 years or older and 11% were 70 years or older. Among HIV\(^+\) participants, the corresponding figures were 9% and 3%. However, given the separation of the gait speed trajectories at the age 50 years and the steeper rate of decline among the HIV\(^+\) observed in this study, it is likely that the negative association between HIV infection and decline in gait speed would be amplified with advancing age. Future analyses of this cohort as it continues to age will help confirm this hypothesis.

The HIV\(^+\) men in the MACS may not be generalizable to other aging HIV\(^+\) populations, as long-standing participants of HIV cohort studies are likely to be different from the general HIV\(^+\) population. Moreover, 9% of MACS participants are 65 years or older compared with 5% of persons living with HIV in the United States,\(^39\) and many of these participants survived a period of time without effective treatment (ie, before 1996) and/or exposure to less effective and more toxic antiretroviral therapy regimens before achieving virologic suppression. Our results do not show a difference in gait speed and disability by experiences before effective treatment (specifically by d-drug usage); if there is, however, an unmeasured effect, the difference in gait speed and disability by HIV status may decrease in an era of effective accessible treatment and antiretroviral therapy initiation at higher CD4 counts. Furthermore, this study did not include women, limiting its generalizability to women aging with HIV.

As the treatment of HIV expands globally, the need to manage and treat age-related conditions in persons living with HIV will grow exponentially. The 57% increased hazard of developing slowed gait holds significant implications for the care of those aging with HIV who may be at increased risk of lower extremity limitations, hospitalization, and death. Accordingly, efforts to prevent and treat mobility loss in those aging with HIV should be a major public health focus. Given recent evidence from the general population, promoting physical activity and a healthy lifestyle are the best current options.\(^40\)

REFERENCES


